Monday, May 15, 2023 Washington D.C. – As the leader of the liver cancers community, Global Liver Institute proudly supports President Biden’s nomination of Monica Bertagnolli, MD, to be the Director of the National Institutes of Health (NIH). Dr. Bertagnolli was the first woman to serve as the director of the National Cancer Institute and before that, as chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She has been a professor of surgery at Harvard Medical School, was recently elected to the National Academy of Medicine and served as the president of the American Society of Clinical Oncology.

“All of us here at Global Liver Institute are grateful for President Biden nominating Dr. Monica Bertagnolli to be the next NIH director,” said Donna R. Cryer, JD, founder and CEO of Global Liver Institute. “We appreciate that Dr. Bertagnolli is a cancer survivor and will continue to drive forward the Cancer Moonshot goals to end cancer as we know it. With her background, coming from rural America, she brings a unique and fundamental understanding of the challenges people face with access to health care. We share her concern that clinical trials need to be more diverse, a significant challenge for liver disease and cancers that disproportionately affect people of color. We are excited to work with Dr. Bertagnolli as she leads NIH with a focus on collaboration, as she has demonstrated in her leadership of the National Cancer Institute.”